Incyte Corporation Company Profile (NASDAQ:INCY)

About Incyte Corporation (NASDAQ:INCY)

Incyte Corporation logoIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:INCY
  • CUSIP: 45337C10
  • Web:
  • Market Cap: $27.90665 billion
  • Outstanding Shares: 204,774,000
Average Prices:
  • 50 Day Moving Avg: $124.12
  • 200 Day Moving Avg: $123.48
  • 52 Week Range: $71.75 - $153.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 336.68
  • P/E Growth: -3.77
Sales & Book Value:
  • Annual Revenue: $1.23 billion
  • Price / Sales: 22.42
  • Book Value: $4.72 per share
  • Price / Book: 28.53
  • EBIDTA: $35.53 million
  • Net Margins: -8.72%
  • Return on Equity: -20.09%
  • Return on Assets: -6.64%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 2.69%
  • Quick Ratio: 2.68%
  • Average Volume: 2.05 million shs.
  • Beta: 0.84
  • Short Ratio: 1.96

Frequently Asked Questions for Incyte Corporation (NASDAQ:INCY)

What is Incyte Corporation's stock symbol?

Incyte Corporation trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte Corporation's earnings last quarter?

Incyte Corporation (NASDAQ:INCY) issued its earnings results on Thursday, May, 4th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.97) by $0.01. The business earned $384.08 million during the quarter, compared to analysts' expectations of $359.19 million. Incyte Corporation had a negative return on equity of 20.09% and a negative net margin of 8.72%. Incyte Corporation's quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.12 EPS. View Incyte Corporation's Earnings History.

Where is Incyte Corporation's stock going? Where will Incyte Corporation's stock price be in 2017?

21 brokers have issued 12-month price targets for Incyte Corporation's shares. Their predictions range from $98.00 to $185.00. On average, they expect Incyte Corporation's share price to reach $143.33 in the next year. View Analyst Ratings for Incyte Corporation.

What are analysts saying about Incyte Corporation stock?

Here are some recent quotes from research analysts about Incyte Corporation stock:

  • 1. Cowen and Company analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)
  • 2. According to Zacks Investment Research, "Incyte’s first-quarter results were encouraging as the company reported a narrower-than-expected loss and surpassed revenue expectations. The growth in Jakafi sales is driven by patient demand and should boost revenues. While most of the demand is due to a larger established patient base in myelofibrosis, polycythemia vera is also expected to be a major long-term driver of Jakafi growth. This is owing to the larger potential patient population and the possibility for longer duration of treatment. The company exited the first quarter with approximately 10,000 patients being treated with Jakafi. However, Incyte’s dependence on a single product, Jakafi, for growth is concerning. Moreover, the FDA has issued a CRL to new drug application (NDA) for baricitinib asking for additional information. The delay in approval is disappointing. Moreover, loss estimates for 2017 have widened significantly following the first-quarter results." (5/23/2017)
  • 3. Instinet analysts commented, "Incyte has been incrementally expanding the opportunity for its JAK franchise in oncology and autoimmune. We anticipate near-term upside from novel JAK combos, formulations, and applications in oncology and autoimmune disease. These under-recognized programs represent $25/sh of our target price and, in our view, offer lower-risk opportunities vs. epacadostat." (3/1/2017)

Are investors shorting Incyte Corporation?

Incyte Corporation saw a decrease in short interest in June. As of June 15th, there was short interest totalling 3,023,910 shares, a decrease of 27.7% from the May 31st total of 4,182,735 shares. Based on an average daily volume of 1,929,555 shares, the short-interest ratio is presently 1.6 days. Currently, 1.5% of the company's shares are short sold.

Who are some of Incyte Corporation's key competitors?

Who are Incyte Corporation's key executives?

Incyte Corporation's management team includes the folowing people:

  • Herve Hoppenot, Chairman of the Board, President, Chief Executive Officer
  • David W. Gryska, Chief Financial Officer, Executive Vice President
  • Reid M. Huber, Executive Vice President, Chief Scientific Officer
  • Eric H. Siegel, Executive Vice President, General Counsel
  • Paula J. Swain, Executive Vice President - Human Resources
  • Barry P. Flannelly, Executive Vice President and General Manager , US
  • Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development`
  • Wenqing Yao Ph.D., Executive Vice President, Head of Discovery Chemistry
  • Steven H. Stein M.D., Vice President and Chief Medical Officer
  • Julian C. Baker, Lead Independent Director

Who owns Incyte Corporation stock?

Incyte Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (16.80%), Vanguard Group Inc. (8.14%), State Street Corp (3.70%), BB Biotech AG (1.84%), FMR LLC (1.57%) and Brown Capital Management LLC (0.99%). Company insiders that own Incyte Corporation stock include Barry P Flannelly, David W Gryska, Eric H Siegel, Jean Jacques Bienaime, Julian Baker, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Richard S Levy, Steven H Stein and Yao Wenqing. View Institutional Ownership Trends for Incyte Corporation.

Who sold Incyte Corporation stock? Who is selling Incyte Corporation stock?

Incyte Corporation's stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Nicholas Investment Partners LP, Marshall Wace LLP, Brown Capital Management LLC, Point72 Asset Management L.P., BB Biotech AG, Cibc World Markets Corp and Tekla Capital Management LLC. Company insiders that have sold Incyte Corporation stock in the last year include Barry P Flannelly, David W Gryska, Eric H Siegel, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber and Steven H Stein. View Insider Buying and Selling for Incyte Corporation.

Who bought Incyte Corporation stock? Who is buying Incyte Corporation stock?

Incyte Corporation's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Victory Capital Management Inc., Geode Capital Management LLC, Morgan Stanley, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P. and UBS Asset Management Americas Inc.. Company insiders that have bought Incyte Corporation stock in the last two years include Jean Jacques Bienaime and Julian Baker. View Insider Buying and Selling for Incyte Corporation.

How do I buy Incyte Corporation stock?

Shares of Incyte Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte Corporation's stock price today?

One share of Incyte Corporation stock can currently be purchased for approximately $134.67.

MarketBeat Community Rating for Incyte Corporation (NASDAQ INCY)
Community Ranking:  4.0 out of 5 (   )
Outperform Votes:  745 (Vote Outperform)
Underperform Votes:  193 (Vote Underperform)
Total Votes:  938
MarketBeat's community ratings are surveys of what our community members think about Incyte Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Incyte Corporation (NASDAQ:INCY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 18 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $143.33 (6.43% upside)

Analysts' Ratings History for Incyte Corporation (NASDAQ:INCY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/20/2017Jefferies Group LLCReiterated RatingBuy$148.00MediumView Rating Details
6/10/2017Credit Suisse GroupReiterated RatingBuyMediumView Rating Details
6/6/2017Oppenheimer Holdings, Inc.Set Price TargetHold$135.00LowView Rating Details
6/6/2017Barclays PLCReiterated RatingOverweight$180.00MediumView Rating Details
6/5/2017BMO Capital MarketsReiterated RatingOutperform$155.00 -> $166.00MediumView Rating Details
6/5/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
5/31/2017CIBCBoost Price TargetOutperform$125.00 -> $135.00LowView Rating Details
5/18/2017J P Morgan Chase & CoSet Price TargetBuy$149.00MediumView Rating Details
5/19/2017Morgan StanleyReiterated RatingOverweight$142.00MediumView Rating Details
4/19/2017SunTrust Banks, Inc.Lower Price TargetBuy$160.00 -> $145.00LowView Rating Details
4/18/2017Goldman Sachs Group, Inc. (The)Lower Price TargetBuy$149.00 -> $136.00LowView Rating Details
4/17/2017Raymond James Financial, Inc.Reiterated RatingHoldHighView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
4/10/2017GabelliInitiated CoverageBuy -> Buy$185.00MediumView Rating Details
4/4/2017Royal Bank Of CanadaBoost Price TargetOutperform$138.00 -> $157.00LowView Rating Details
3/21/2017William BlairInitiated CoverageOutperformLowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
9/26/2016ArgusBoost Price TargetBuy$92.00 -> $98.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
1/31/2016Bank of America CorporationReiterated RatingBuy$145.00 -> $87.00N/AView Rating Details
11/19/2015UBS AGReiterated RatingBuy$130.00N/AView Rating Details
(Data available from 6/27/2015 forward)


Earnings History for Incyte Corporation (NASDAQ:INCY)
Earnings by Quarter for Incyte Corporation (NASDAQ:INCY)
Earnings History by Quarter for Incyte Corporation (NASDAQ INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Incyte Corporation (NASDAQ:INCY)
2017 EPS Consensus Estimate: ($0.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.01)($0.82)($0.93)
Q2 20175($0.08)$0.61$0.28
Q3 20174($0.08)$0.32$0.12
Q4 20175($0.06)$0.27$0.09
(Data provided by Zacks Investment Research)


Dividend History for Incyte Corporation (NASDAQ:INCY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Incyte Corporation (NASDAQ:INCY)
Insider Ownership Percentage: 13.70%
Institutional Ownership Percentage: 92.79%
Insider Trades by Quarter for Incyte Corporation (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)
Insider Trades by Quarter for Incyte Corporation (NASDAQ:INCY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/20/2017Steven H SteinEVPSell9,883$125.00$1,235,375.00View SEC Filing  
6/12/2017David W GryskaCFOSell16,756$116.60$1,953,749.60View SEC Filing  
6/5/2017Paul TrowerInsiderSell3,000$132.50$397,500.00View SEC Filing  
6/1/2017Eric H SiegelEVPSell1,820$130.00$236,600.00View SEC Filing  
5/31/2017Jean Jacques BienaimeDirectorBuy500$131.80$65,900.00View SEC Filing  
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.00View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.17View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.60View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.00View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.00View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.00View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.74View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.00View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.00View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.00View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.00View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.00View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Incyte Corporation (NASDAQ:INCY)
Latest Headlines for Incyte Corporation (NASDAQ:INCY)
DateHeadline logoIncyte Corporation (INCY) EVP Sells $1,235,375.00 in Stock - June 22 at 7:28 PM logoSmall Cancer Biotech Space in Focus, 3 Stocks Up 100% & More - June 21 at 3:36 PM logo4 Stocks & ETFs to Buy on Clovis' Positive Drug Data - June 21 at 3:36 PM logo$316.11 Million in Sales Expected for Incyte Corporation (INCY) This Quarter - June 21 at 9:28 AM logoIncyte Corporation (INCY) Receives Buy Rating from Jefferies Group LLC - June 20 at 1:40 PM logoZacks: Analysts Expect Incyte Corporation (INCY) Will Announce Earnings of -$0.04 Per Share - June 19 at 6:46 PM logoIncyte Corporation Expected to Post Q4 2017 Earnings of $0.18 Per Share (INCY) - June 19 at 7:21 AM logoIncyte (INCY) Presents At The William Blair 2017 Growth Stock Conference - Slideshow - June 16 at 5:25 AM logoHow Did Incyte’s Product Portfolio Look in 1Q17? - June 16 at 5:25 AM logoHow Incyte’s Jakafi Performed in 1Q17 - June 16 at 5:25 AM logoNew Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017 - June 16 at 5:25 AM logoInsider Selling: Incyte Corporation (INCY) CFO Sells 16,756 Shares of Stock - June 14 at 10:31 PM logoIncyte Corporation (INCY) Given Buy Rating at Credit Suisse Group - June 11 at 11:32 PM logoIncyte (INCY) Up 3.4% Since Earnings Report: Can It Continue? - Nasdaq - June 11 at 11:11 PM logoIncyte Co. (INCY) Earns "Overweight" Rating from Barclays PLC - June 11 at 12:46 PM logoCORRECTED-UPDATE 3-AbbVie's rheumatoid arthritis drug succeeds in trial - June 7 at 11:31 PM logoInsider Selling: Incyte Co. (INCY) Insider Sells 3,000 Shares of Stock - June 7 at 7:50 PM logoAbbVie's rheumatoid arthritis drug succeeds in trial - June 7 at 5:30 PM logoIncyte Co. (INCY) Given a $135.00 Price Target at Oppenheimer Holdings Inc. - June 7 at 4:50 PM logoUPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage trial - June 7 at 10:05 AM logoSolid Progress For IDO Inhibitors - June 7 at 10:05 AM logoIncyte Co. (INCY) Given Consensus Rating of "Buy" by Brokerages - June 6 at 12:52 PM logoBMO Capital Markets Reiterates Outperform Rating for Incyte Co. (INCY) - June 5 at 10:00 PM logoCowen and Company Reiterates Buy Rating for Incyte Co. (INCY) - June 5 at 9:22 PM logoMissing Patients Cloud View of Incyte's IDO Drug Lung Cancer Study - June 4 at 11:05 PM logoIncyte Co. (INCY) Upgraded at ValuEngine - June 4 at 11:14 AM logoIncyte 'IDO' Combination Lung Cancer Results Improve Slightly at ... - - June 4 at 10:37 AM logoCombination of Incyte's epacadostat plus Merck's Ketyruda demonstrates activity in trial of patients with advanced non-small cell lung cancer - June 3 at 4:37 PM logoAll eyes at ASCO on updated results from Incyte/Merck combo trial - June 3 at 12:29 PM logoIncyte Co. (INCY) Director Jean Jacques Bienaime Acquires 500 Shares - June 2 at 8:42 PM logoIncyte Co. (INCY) EVP Eric H. Siegel Sells 1,820 Shares - June 2 at 8:20 PM logo15 Companies Bracing for Big ASCO Reactions - June 2 at 7:19 PM logoA Hot Cancer-Drug Race Keeps Getting More Crowded - June 2 at 7:19 PM logo[$$] Four things to watch at the Asco cancer meeting - June 1 at 6:43 PM logoIncyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : June 1, 2017 - June 1 at 6:43 PM logoIncyte Co. Expected to Post FY2019 Earnings of $2.09 Per Share (INCY) - June 1 at 2:48 PM logoIncyte Co. (INCY) Price Target Raised to $135.00 - May 31 at 5:36 PM logoIncyte Co. (INCY) Given "Outperform" Rating at Oppenheimer Holdings Inc. - May 31 at 1:17 PM logoPREVIEW-Cancer meeting to provide clues on future immunotherapy combos - May 31 at 8:26 AM logoTraders Buy Large Volume of Call Options on Incyte (INCY) - May 30 at 6:50 PM logoIncyte Co. (INCY) Price Target Raised to $146.00 - May 29 at 4:42 PM logoIncyte's (INCY) "Buy" Rating Reiterated at Cowen and Company - May 29 at 4:42 PM logoIncyte Co. (INCY) Stock Rating Upgraded by TheStreet - May 27 at 7:32 AM logoIncyte Co. (INCY) Expected to Post Quarterly Sales of $316.31 Million - May 26 at 4:02 PM logo Analysts Anticipate Incyte Co. (INCY) to Announce $0.01 Earnings Per Share - May 24 at 2:14 PM logoBlog Coverage: Amgen Announces New Data from the FOURIER Trial - May 23 at 11:17 AM logoIncyte Co. (INCY) Raised to Hold at Zacks Investment Research - May 23 at 9:26 AM logoIncyte's (INCY) Overweight Rating Reaffirmed at Morgan Stanley - May 20 at 7:40 AM logoJPMorgan Chase & Co. Reiterates "$149.00" Price Target for Incyte Co. (INCY) - May 19 at 7:16 PM logoIncyte Co. (INCY) PT Set at $125.00 by Oppenheimer Holdings Inc. - May 19 at 5:54 PM



Incyte Corporation (INCY) Chart for Tuesday, June, 27, 2017

This page was last updated on 6/27/2017 by Staff